FIELD: medicine; therapy; neurology.
SUBSTANCE: group of inventions is intended for the treatment and/or prevention of a demyelinating disease in a subject. A pharmaceutical composition containing nalfurafine is used to (i) treat a demyelinating disease in a subject, (ii) increase nerve remyelination in a subject, or (iii) attenuate nerve demyelination in a subject. Also a method of (i) treating a demyelinating disease in a subject, (ii) increasing nerve remyelination in a subject, or (iii) attenuating nerve demyelination in a subject comprising administering to the subject a pharmaceutical composition containing nalfurafine is provided. In another embodiment, the use of nalfurafine is disclosed for the preparation of a pharmaceutical composition for (i) treating a demyelinating disease in a subject, (ii) increasing nerve remyelination in a subject, or (iii) attenuating nerve demyelination in a subject.
EFFECT: use of the group of inventions provides effective treatment of a demyelinating disease in a subject, and also makes it possible to increase nerve remyelination in a subject or weaken nerve demyelination in a subject.
18 cl, 32 dwg, 1 tbl, 32 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW METHODS FOR TREATING MULTIPLE SCLEROSIS | 2018 |
|
RU2765820C2 |
| ANIMAL MODEL EXPRESSING LUCIFERASE UNDER CONTROL OF THE MYELIN BASIC PROTEIN PROMOTER (MBP-LUCI) AND USE OF THE MODEL FOR BIOLUMINESCENCE IN VIVO IMAGING | 2010 |
|
RU2601128C2 |
| COMPOSITION AND METHOD OF AUTOIMMUNE DISEASES TREATMENT | 2012 |
|
RU2621129C2 |
| METHODS AND TREATMENT OF CERTAIN DISORDERS BASED ON DEMYELINATION AND DEMYELINATION AND/OR REMYELINATION STIMULATION | 2014 |
|
RU2686677C2 |
| NEW TREATMENT OF MULTIPLE SCLEROSIS (MS) | 2011 |
|
RU2595861C2 |
| METHOD OF TREATING MULTIPLE SCLEROSIS | 2010 |
|
RU2539034C2 |
| GENE-CELL VESICULAR THERAPEUTIC DRUG AND METHOD FOR MULTIPLE SCLEROSIS THERAPY BY TRANSPLANTATION OF A GENE-CELL VESICULAR THERAPEUTIC DRUG | 2021 |
|
RU2762855C1 |
| LIPOSOMES CONTAINING OLIGOPEPTIDE FRAGMENTS OF MYELIN BASIC PROTEIN, PHARMACEUTICAL COMPOSITION AND METHOD FOR MULTIPLE SCLEROSIS TREATMENT | 2013 |
|
RU2639497C2 |
| SOBETIROME DERIVATIVES | 2017 |
|
RU2776372C2 |
| PEPTIDE | 2014 |
|
RU2675479C2 |
